EBS:NYSE
新兴生物科技公司
US$6.91
0.00%
(0.00) 1 天
US$6.80
arrow_downward
-1.59% (-0.11)today开盘前
休市： 10月14日, GMT-4 16:00:03 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 EBS 生成关键数据洞见…
开盘价
US$6.87
最高价
US$7.07
最低价
US$6.81
市值
3.54亿
平均成交量
113.61万
成交量
4137.00
52 周最高价
US$14.06
52 周最低价
US$4.36
每股收益
-US$3.51
Beta 版
2.28
流通股数
5127.30万
员工人数
900
开盘价
US$6.87
最高价
US$7.07
最低价
US$6.81
市值
3.54亿
平均成交量
113.61万
成交量
4137.00
52 周最高价
US$14.06
52 周最低价
US$4.36
每股收益
-US$3.51
Beta 版
2.28
流通股数
5127.30万
员工人数
900
新闻报道
来自网络来源和新闻合作伙伴
资料
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
新兴生物科技公司简介